X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5268) 5268
Newsletter (224) 224
Newspaper Article (187) 187
Transcript (94) 94
Magazine Article (70) 70
Book / eBook (4) 4
Book Review (4) 4
Dissertation (1) 1
Publication (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4576) 4576
anticholesteremic agents - therapeutic use (2750) 2750
male (2728) 2728
female (2390) 2390
anticholesteremic agents - adverse effects (2105) 2105
middle aged (2062) 2062
cholesterol (1693) 1693
anticholesteremic agents (1618) 1618
aged (1545) 1545
hypercholesterolemia - drug therapy (1378) 1378
adult (1249) 1249
cholesterol, ldl - blood (1243) 1243
risk factors (1103) 1103
statins (1063) 1063
anticholesteremic agents - administration & dosage (1018) 1018
treatment outcome (990) 990
hypercholesterolemia (968) 968
pharmacology & pharmacy (836) 836
simvastatin (824) 824
animals (821) 821
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (811) 811
cardiac & cardiovascular systems (799) 799
cholesterol - blood (766) 766
anticholesteremic agents - pharmacology (760) 760
medicine, general & internal (718) 718
lipids (692) 692
drug therapy, combination (679) 679
low density lipoproteins (665) 665
ezetimibe (645) 645
double-blind method (636) 636
atherosclerosis (635) 635
atorvastatin (617) 617
hypercholesterolemia - blood (602) 602
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (585) 585
drug therapy (562) 562
cardiovascular disease (538) 538
coronary-heart-disease (514) 514
prevention (505) 505
atorvastatin calcium (499) 499
cardiovascular diseases - prevention & control (494) 494
risk (483) 483
triglycerides - blood (481) 481
cholesterol, hdl - blood (480) 480
research (469) 469
care and treatment (467) 467
pravastatin (456) 456
safety (447) 447
efficacy (412) 412
analysis (405) 405
lipids - blood (402) 402
cardiovascular diseases (397) 397
health aspects (379) 379
heptanoic acids - therapeutic use (379) 379
abridged index medicus (369) 369
dose-response relationship, drug (369) 369
mortality (368) 368
cardiovascular agents (359) 359
pyrroles - therapeutic use (357) 357
clinical trials (351) 351
hyperlipidemias - drug therapy (351) 351
therapy (350) 350
coronary heart disease (343) 343
lipoproteins (335) 335
azetidines - therapeutic use (333) 333
cardiovascular (326) 326
simvastatin - therapeutic use (325) 325
drug interactions (324) 324
time factors (322) 322
density-lipoprotein cholesterol (316) 316
diabetes (316) 316
peripheral vascular disease (313) 313
aged, 80 and over (310) 310
medicine & public health (310) 310
medical research (308) 308
randomized controlled trials as topic (308) 308
disease (304) 304
cardiovascular-disease (299) 299
simvastatin - adverse effects (299) 299
heptanoic acids - adverse effects (295) 295
dyslipidemias - drug therapy (291) 291
double-blind (288) 288
biomarkers - blood (285) 285
statin therapy (284) 284
internal medicine (282) 282
prospective studies (281) 281
pyrroles - adverse effects (281) 281
follow-up studies (278) 278
cardiology (276) 276
triglycerides (270) 270
clinical trials as topic (269) 269
antilipemic agents (268) 268
endocrinology & metabolism (267) 267
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (267) 267
adolescent (265) 265
rats (265) 265
hypercholesterolemia - complications (260) 260
myocardial-infarction (259) 259
hyperlipidemia (252) 252
physiological aspects (249) 249
hypolipidemic agents - therapeutic use (245) 245
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5476) 5476
German (120) 120
French (66) 66
Spanish (40) 40
Japanese (32) 32
Swedish (29) 29
Russian (21) 21
Italian (17) 17
Danish (15) 15
Dutch (15) 15
Norwegian (15) 15
Chinese (14) 14
Hungarian (8) 8
Portuguese (7) 7
Polish (6) 6
Czech (3) 3
Croatian (2) 2
Finnish (2) 2
Hebrew (2) 2
Lithuanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Current medical research and opinion, ISSN 1473-4877, 2012, Volume 29, Issue 1, pp. 1 - 12
...-related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin... 
Rifabutin | Rifampin | Rifapentine | Drug interactions | MEDICINE, RESEARCH & EXPERIMENTAL | ENZYME-INDUCTION | PLATELET-AGGREGATION | ATORVASTATIN | SINGLE-BLIND | MEDICINE, GENERAL & INTERNAL | CLOPIDOGREL | PHARMACOKINETICS | METABOLISM | PLASMA-CONCENTRATIONS | HEALTHY-VOLUNTEERS | TRANSPORTER INHIBITION | Rifampin - analogs & derivatives | Simvastatin - therapeutic use | Antifungal Agents - adverse effects | Digoxin - adverse effects | Simvastatin - adverse effects | Antibiotics, Antitubercular - adverse effects | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Antifungal Agents - therapeutic use | Rifampin - adverse effects | Verapamil - therapeutic use | Drug Interactions | Verapamil - adverse effects | Rifampin - therapeutic use | Contraceptives, Oral - adverse effects | Contraceptives, Oral - therapeutic use | Digoxin - therapeutic use | HIV Protease Inhibitors - adverse effects | Rifabutin - adverse effects | Anti-Arrhythmia Agents - therapeutic use | HIV Protease Inhibitors - therapeutic use | Anticholesteremic Agents - adverse effects | Itraconazole - therapeutic use | Anticholesteremic Agents - therapeutic use | Anti-Arrhythmia Agents - adverse effects | Itraconazole - adverse effects | Antibiotics, Antitubercular - therapeutic use | Cytochrome P-450 Enzyme System - biosynthesis | Rifabutin - therapeutic use | ATP Binding Cassette Transporter, Sub-Family B | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 22, pp. 2078 - 2087
In this trial, intravascular ultrasonography was used to compare the effects of atorvastatin versus rosuvastatin on regression of coronary atherosclerosis... 
MEDICINE, GENERAL & INTERNAL | EVENTS | MYOCARDIAL-INFARCTION | CHOLESTEROL | EFFICACY | ATHEROSCLEROSIS | PREVENTION | INTRAVASCULAR ULTRASOUND | PRAVASTATIN | ROSUVASTATIN | ATORVASTATIN | Coronary Vessels - diagnostic imaging | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Ultrasonography, Interventional | Male | Heptanoic Acids - adverse effects | Coronary Artery Disease - pathology | Pyrroles - adverse effects | Cholesterol, LDL - blood | Female | Pyrroles - therapeutic use | Coronary Vessels - pathology | Double-Blind Method | Rosuvastatin Calcium | Coronary Artery Disease - drug therapy | Anticholesteremic Agents - adverse effects | Disease Progression | Atorvastatin Calcium | Coronary Artery Disease - diagnostic imaging | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Cholesterol, HDL - blood | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Fluorobenzenes - therapeutic use | Drugs | Rosuvastatin | Dosage and administration | Product/Service Evaluations | Drug therapy | Atherosclerosis | Lipoproteins (low density) | Clinical trials | Cardiovascular disease | Patients | Cholesterol | Studies | Side effects | Ultrasonic imaging | Arteriosclerosis | Atorvastatin | Heart diseases | Lipoproteins (high density) | Ultrasound | Statins
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2012, Volume 60, Issue 20, pp. 2041 - 2048
Journal Article
Journal Article
Cochrane library, ISSN 1465-1858, 2017, Volume 2017, Issue 3, p. CD009868
...‐fatal ASCVD events, and adverse events. We also sought to determine the effect of fixed... 
Blood Pressure | Drugs | A.1 Drugs | Anticholesteremic Agents | Aspirin | Cardiovascular Diseases | Heart disease prevention | Costs | A.1.3 Other | Placebo Effect | A. Cardiovascular Disease: Primary Prevention | Insurance medicine | Cause of Death | Cholesterol | Randomized Controlled Trials as Topic | Prevention | Platelet Aggregation Inhibitors | Antihypertensive Agents | Heart & circulation | Medicine General & Introductory Medical Sciences | Drug Combinations | POLYPILL-BASED STRATEGY | Humans | Antihypertensive Agents [administration & dosage] | Anticholesteremic Agents [administration & dosage] | Cardiovascular Diseases [mortality; prevention & control] | RANDOMIZED CONTROLLED-TRIAL | PROACTIVE MULTIFACTORIAL INTERVENTION | Aspirin [administration & dosage] | USUAL CARE | MEDICINE, GENERAL & INTERNAL | Platelet Aggregation Inhibitors [administration & dosage] | HIGH-RISK | DOUBLE-BLIND | SINGLE-PILL COMBINATION | BLOOD-PRESSURE CONTROL | PLACEBO-CONTROLLED TRIAL | CORONARY-HEART-DISEASE | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Anticholesteremic Agents - adverse effects | Antihypertensive Agents - adverse effects | Aspirin - administration & dosage | Aspirin - adverse effects | Anticholesteremic Agents - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Platelet Aggregation Inhibitors - adverse effects
Journal Article
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1580 - 1590
Journal Article
Endocrine journal, ISSN 0918-8959, 2014, Volume 61, Issue 4, pp. 365 - 372
The effects of exenatide on glycemic control, lipid metabolism, blood pressure, and gastrointestinal symptoms were investigated in obese Japanese patients with type 2 diabetes mellitus... 
Obesity | Incretin | Type 2 diabetes mellitus | Exenatide | GLYCEMIC CONTROL | GLP-1 | ENDOCRINOLOGY & METABOLISM | Follow-Up Studies | Nausea - chemically induced | Obesity - drug therapy | Humans | Middle Aged | Gastrointestinal Agents - administration & dosage | Antihypertensive Agents - administration & dosage | Anti-Obesity Agents - adverse effects | Male | Diabetes Mellitus, Type 2 - metabolism | Weight Loss - drug effects | Obesity - blood | Anti-Obesity Agents - therapeutic use | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Glucagon-Like Peptide 1 - agonists | Injections, Subcutaneous | Venoms - administration & dosage | Adult | Female | Diabetes Mellitus, Type 2 - complications | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Anti-Obesity Agents - administration & dosage | Obesity - complications | Venoms - adverse effects | Japan | Antihypertensive Agents - therapeutic use | Anticholesteremic Agents - adverse effects | Antihypertensive Agents - adverse effects | Obesity - metabolism | Diabetes Mellitus, Type 2 - blood | Anticholesteremic Agents - therapeutic use | Anticholesteremic Agents - administration & dosage | Gastrointestinal Agents - therapeutic use | Venoms - therapeutic use | Aged | Gastrointestinal Agents - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Peptides - therapeutic use
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 25, pp. 2387 - 2397
In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At... 
no | CHOLESTEROL ABSORPTION | CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | CARDIOVASCULAR OUTCOMES | CLINICAL-TRIALS | SIMVASTATIN | PRIMARY PREVENTION | IMPROVE-IT | ATORVASTATIN | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article